IMGT® databases, related tools and web resources through three main axes of research and development.

IMGT®, the international ImMunoGeneTics information system®, http://www.imgt.org/, is at the forefront of the immunogenetics and immunoinformatics fields with more than 30 years of experience. IMGT® makes available databases and tools to the scientific community pertaining to the adaptive immune response, based on the IMGT-ONTOLOGY. We focus on the recent features of the IMGT® databases, tools, reference directories and web resources, within the three main axes of IMGT® research and development. Axis I consists in understanding the adaptive immune response, by deciphering the identification and characterization of the immunoglobulin (IG) and T cell receptor (TR) genes in jawed vertebrates. It is the starting point of the two other axes, namely the analysis and exploration of the expressed IG and TR repertoires based on comparison with IMGT reference directories in normal and pathological situations (Axis II) and the analysis of amino acid changes and functions of 2D and 3D structures of antibody and TR engineering (Axis III).

Sustainable green synthesis of Hedychium coronarium leaf extract-stabilized silver nanoparticles and their applications: colorimetric sensing of Sn2+ and Hg2+ and antifungal and antimicrobial properties.

Hedychium coronarium (Hc) (commonly known as Gulbakawali) leaf extract was used for the stable and sustainable green synthesis of silver nanoparticles (Hc-AgNPs), which were biodegradable and non-toxic. Hedychium coronarium leaf extract was used as a reducing agent to stabilize the Hc-AgNPs by converting Ag+ to Ag0 without adding any capping agent. It demonstrated stability for up to six months, and no agglomeration was observed. The Hc-AgNPs were characterized using X-ray diffraction (XRD), Fourier-transform infrared spectroscopy (FT-IR), transmission electron microscopy (TEM), ultraviolet-visible spectrophotometry, and fluorescence spectroscopy analysis. The UV-visible spectrum supported the formation of stable Hc-AgNPs by displaying a strong surface plasmon resonance (SPR) peak at 440 nm. FT-IR spectra showed the functional groups present in the leaf extract of Hedychium coronarium, which was the primary source of secondary metabolites attached to Ag0. XRD analysis revealed a distinct 2θ peak of Hc-AgNPs at 38.15°, indicating a face-centred cubic structure with a crystallite size of 22.6 ± 1 nm at the (111) plane. Moreover, TEM demonstrated the spherical morphology of the Hc-AgNPs with an average particle size of 22.42 ± 1 nm. The photophysical characteristics of the Hc-AgNPs, as highlighted by their UV-vis and fluorescence characteristics, revealed their semiconducting nature with an impressive band gap (E g) value of 3.78 eV. Fascinatingly, the fluorescence activity of Hc-AgNPs at 504 nm showed a broad emission band corresponding to the absorption band at 251 nm. We performed the selective colorimetric sensing of Sn2+ metal ions using Hc-AgNPs, which demonstrated a detection limit of 10-3 M, suggesting their potential as very good solid biosensors. Interestingly, the Hc-AgNPs showed antifungal activity, which has not been reported before. Specifically, the results showed that the Hc-AgNPs had a higher fungitoxicity effect against Aspergillus flavus (59.58 ± 3.68) than against Fusarium oxysporum (57.93 ± 4.18). The antibacterial activity of the Hc-AgNPs was evaluated against three Gram-negative phytopathogenic bacteria: Xanthomonas oryzae (X. oryzae), Ralstonia solanacearum (R. solanacearum), and Erwinia carotovora (E. carotovora), showing effective inhibition zones of 16.33 ± 0.57, 15.33 ± 0.57, and 14.33 ± 0.57 mm, respectively. These results indicate that the Hc-AgNPs could inhibit these phytopathogenic bacteria with varying degrees of effectiveness in the order of X. oryzae > R. solanacearum > E. carotovora.

Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB.

Background: Cancer cells activate different immune checkpoint (IC) pathways in order to evade immunosurveillance. Immunotherapies involving ICs either block or stimulate these pathways and enhance the efficiency of the immune system to recognize and attack cancer cells. In this way, the development of monoclonal antibodies (mAbs) targeting ICs has significant success in cancer treatment. Recently, a systematic description of the mechanisms of action (MOA) of the mAbs has been introduced in IMGT/mAb-DB, the IMGT® database dedicated to mAbs for therapeutic applications. The characterization of these antibodies provides a comprehensive understanding of how mAbs work in cancer. Methods: In depth biocuration taking advantage of the abundant literature data as well as amino acid sequence analyses from mAbs managed in IMGT/2Dstructure-DB, the IMGT® protein database, allowed to define a standardized and consistent description of the MOA of mAbs targeting immune checkpoints in cancer therapy. Results: A fine description and a standardized graphical representation of the MOA of selected mAbs are integrated within IMGT/mAb-DB highlighting two main mechanisms in cancer immunotherapy, either Blocking or Agonist. In both cases, the mAbs enhance cytotoxic T lymphocyte (CTL)-mediated anti-tumor immune response (Immunostimulant effect) against tumor cells. On the one hand, mAbs targeting co-inhibitory receptors may have a functional Fc region to increase anti-tumor activity by effector properties that deplete Treg cells (Fc-effector function effect) or may have limited FcγR binding to prevent Teff cells depletion and reduce adverse events. On the other hand, agonist mAbs targeting co-stimulatory receptors may bind to FcγRs, resulting in antibody crosslinking (FcγR crosslinking effect) and substantial agonism. Conclusion: In IMGT/mAb-DB, mAbs for cancer therapy are characterized by their chains, domains and sequence and by several therapeutic metadata, including their MOA. MOAs were recently included as a search criterion to query the database. IMGT® is continuing standardized work to describe the MOA of mAbs targeting additional immune checkpoints and novel molecules in cancer therapy, as well as expanding this study to other clinical domains.